Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes

References

• Maddox TM, Januzzi JLJ, Allen LA, et al. Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversi. J Am Coll Cardiol. 2021;77(6):772–810. doi: 10.1016/j.jacc.2020.11.022.
   PubMed Web of Science ®Google Scholar
• Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure. Eur J Heart Fail. 2020;22(8):1342–1356. doi: 10.1002/ejhf.1858.
   PubMed Web of Science ®Google Scholar
• Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7–11. doi: 10.15420/cfr.2016:25:2.
   PubMedGoogle Scholar
• Elasfar AA, Alhabeeb W, Elasfar S. Heart failure in the Middle east arab countries: current and future perspectives. J Saudi Heart Assoc. 2020;32(2):236–241. https://pubmed.ncbi.nlm.nih.gov/33154923 doi: 10.37616/2212-5043.1040.
   PubMed Web of Science ®Google Scholar
• Cook C, Cole G, Asaria P, et al. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368–376. doi: 10.1016/j.ijcard.2013.12.028.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC)developed with the special contribution o. Eur Heart J. 2016;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. Sep doi: 10.1093/eurheartj/ehab368.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. Nov doi: 10.1056/NEJMoa1911303.
   PubMed Web of Science ®Google Scholar
• McEwan P, Darlington O, McMurray JJV, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020;22(11):2147–2156. doi: 10.1002/ejhf.1978.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhang R, An T, et al. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC Heart Fail. 2020;7(6):3582–3592. doi: 10.1002/ehf2.12844.
   PubMed Web of Science ®Google Scholar
• Savira F, Wang BH, Kompa AR, et al. Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. Eur J Prev Cardiol. 2020;28(9):975–982. Jul;2047487320938272. doi: 10.1177/2047487320938272.
   PubMed Web of Science ®Google Scholar
• Isaza N, Calvachi P, Raber I, et al. Cost-effectiveness of Dapagliflozin for the treatment of heart failure with reduced ejection fraction. JAMA Netw Open. 2021;4(7):e2114501. Jul doi: 10.1001/jamanetworkopen.2021.14501.
   PubMed Web of Science ®Google Scholar
• Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25–32. doi: 10.1177/2047487319878371.
   PubMed Web of Science ®Google Scholar
• Bertoluci MC, Rocha VZ. Cardiovascular risk assessment in patients with diabetes. Diabetol Metab Syndr. 2017;9(1):25. https://pubmed.ncbi.nlm.nih.gov/28435446 doi: 10.1186/s13098-017-0225-1.
   PubMedGoogle Scholar
• Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353–1368. doi: 10.1001/jama.2020.1906.
   PubMed Web of Science ®Google Scholar
• Krittayaphong R, Permsuwan U. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction. Int J Cardiol. 2021;322:183–190. doi: 10.1016/j.ijcard.2020.08.017.
   PubMed Web of Science ®Google Scholar
• Nguyen B-N, Mital S, Bugden S, et al. Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction. Int J Cardiol. 2023;376:83–89. doi: 10.1016/j.ijcard.2023.01.080.
   PubMed Web of Science ®Google Scholar
• Krittayaphong R, Permsuwan U. Cost-utility analysis of Sacubitril-Valsartan compared with enalapril treatment in patients with acute decompensated heart failure in Thailand. Clin Drug Investig. 2021;41(10):907–915. doi: 10.1007/s40261-021-01079-6.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zheng R, Sang H. Cost-effectiveness of adding SGLT2 inhibitors to standard treatment for heart failure with reduced ejection fraction patients in China. Front Pharmacol. 2021;12:733681. doi: 10.3389/fphar.2021.733681.
   PubMed Web of Science ®Google Scholar
• Hussain A, Misra A, Bozkurt B. Endpoints in heart failure drug development. Card Fail Rev. 2022;8:e01. doi: 10.15420/cfr.2021.13.
   PubMedGoogle Scholar
• Zannad F, Garcia AA, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European society of cardiology heart failure association consensus document. Eur J Heart Fail. 2013;15(10):1082–1094. doi: 10.1093/eurjhf/hft095.
   PubMed Web of Science ®Google Scholar
• van der Pol S, Degener F, Postma MJ, et al. An economic evaluation of sacubitril/valsartan for heart failure patients in The Netherlands. Value Health. 2017;20(3):388–396. Mar doi: 10.1016/j.jval.2016.10.015.
   PubMed Web of Science ®Google Scholar
• King JB, Shah RU, Bress AP, et al. Cost-effectiveness of Sacubitril-Valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4(5):392–402. doi: 10.1016/j.jchf.2016.02.007.
   PubMed Web of Science ®Google Scholar
• Backholer K, Hirakawa Y, Tonkin A, et al. Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statistics. BMC Cardiovasc Disord. 2017;17(1):17. doi: 10.1186/s12872-016-0462-5.
   PubMedGoogle Scholar
• Abushanab D, Marquina C, Morton JI, et al. Projecting the health and economic burden of cardiovascular disease among people with type 2 diabetes, 2022–2031. Pharmacoeconomics. 2023;41(6):719–732. doi: 10.1007/s40273-023-01258-7.
   PubMed Web of Science ®Google Scholar
• Yan BW, Spahillari A, Pandya A. Cost-effectiveness of quadruple therapy in management of heart failure with reduced ejection fraction in the United States. Circ Cardiovasc Qual Outcomes. 2023;16(6):e009793. doi: 10.1161/CIRCOUTCOMES.122.009793.
   PubMed Web of Science ®Google Scholar
• Marquina C, Talic S, Vargas-Torres S, et al. Future burden of cardiovascular disease in Australia: impact on health and economic outcomes between 2020 and 2029. Eur J Prev Cardiol. 2022;29(8):1212–1219.
   PubMed Web of Science ®Google Scholar
• Abushanab D, Al-Badriyeh D, Liew D, et al. First-line treatment with empagliflozin and metformin combination versus standard care for patients with type 2 diabetes mellitus and cardiovascular disease in Qatar. A cost-effectiveness analysis. Curr Probl Cardiol. 2021;47(6):100852. doi: 10.1016/j.cpcardiol.2021.100852.
   PubMed Web of Science ®Google Scholar
• Kaddoura R, Abushanab D, Arabi AR, et al. Cost-effectiveness analysis of sacubitril/valsartan for reducing the use of implantable cardioverter-defibrillator (ICD) and the risk of death in ICD-eligible heart failure patients with reduced ejection fraction. Curr Probl Cardiol. 2022;47(12):101385. doi: 10.1016/j.cpcardiol.2022.101385.
   PubMed Web of Science ®Google Scholar
• Al-Badriyeh D, Hssain AA, Abushanab D. Cost-effectiveness analysis of out-of-hospital versus in-hospital extracorporeal cardiopulmonary resuscitation for out-hospital refractory cardiac arrest. Curr Probl Cardiol. 2022;47(12):101387. doi: 10.1016/j.cpcardiol.2022.101387.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. doi: 10.1016/j.jval.2021.11.1351.
   PubMed Web of Science ®Google Scholar
• Hamad Medical Corporation. [Internet]. Available from https://www.hamad.qa/EN/Pages/default.aspx.
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modeling for health economics evaluation. Briggs A, Claxton K, Sculpher M, editors. Oxford: Oxford University Press; 2006.
   Google Scholar
• Ministry of Development Planning and Statistics. Births & Deaths In the State of Qatar, [Internet]. 2016; [cited 2021 Dec 10]. Available from: https://www.psa.gov.qa/en/statistics/Statistical Releases/Population/BirthsDeaths/2016/Birth_death_2016_EN.pdf.
   Google Scholar
• Abushanab D, Liew D, Marquina C, et al. Cost-Effectiveness of empagliflozin and metformin combination versus standard care as first-Line therapy in patients with type 2 diabetes mellitus. Endocr Pract. 2022;28(1):16–24. doi: 10.1016/j.eprac.2021.07.018.
   PubMed Web of Science ®Google Scholar
• Ministry of Development Planning and Statistics. Births & Deaths In the State of Qatar, 2016; [cited 2020 April]. Available from: https://www.psa.gov.qa/en/statistics/Statistical%20Releases/Population/BirthsDeaths/2016/Birth_death_2016_EN.pdf.
   Google Scholar
• Adena MA, Hamann G, Sindone AP. Cost-Effectiveness of ivabradine in the treatment of chronic heart failure. Heart Lung Circ. 2019;28(3):414–422. doi: 10.1016/j.hlc.2018.01.011.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e895–1032.
   Web of Science ®Google Scholar
• Tan YJ, Ong SC, Kan YM. Is using sodium-glucose cotransporter-2 inhibitors to treat adults with chronic heart failure cost-effective? A systematic review of cost-effectiveness studies. Appl Health Econ Health Policy. 2023;21(6):857–875.
   Google Scholar
• Tafazzoli A, Reifsnider OS, Bellanca L, et al. A european multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction. Eur J Health Econ. 2022;24(9):1441–1454. doi: 10.1007/s10198-022-01555-6.
   PubMed Web of Science ®Google Scholar
• Qatar Inflation Rate [Internet]. 2021; [cited 2021 Oct 15]. Available from: https://tradingeconomics.com/qatar/inflation-cpi.
   Google Scholar
• Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plan. 2020;35(1):107–114. doi: 10.1093/heapol/czz127.
   PubMed Web of Science ®Google Scholar
• Adel A, Abushanab D, Hamad A, et al. Assessment of dasatinib versus nilotinib as upfront therapy for chronic phase of chronic myeloid leukemia in Qatar: a cost-effectiveness analysis. Cancer Control. 2021;28:10732748211001796. doi: 10.1177/10732748211001796.
   Web of Science ®Google Scholar
• Abushanab D, Rouf PA, Al Hail M, et al. Cost-effectiveness of oral versus intravenous ibuprofen therapy in preterm infants with patent ductus arteriosus in the neonatal intensive care setting: a cohort-based study. Clin Ther. 2021;43(2):336–348.e7. https://www.sciencedirect.com/science/article/pii/S014929182030552X doi: 10.1016/j.clinthera.2020.12.004.
   PubMed Web of Science ®Google Scholar
• Abushanab D, Alsoukhni O, AbouNahia F, et al. Clinical and economic analysis of morphine versus fentanyl in managing ventilated neonates with respiratory distress syndrome in the intensive care setting. Clin Ther. 2019;41(4):714–727.e8. doi: 10.1016/j.clinthera.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21. doi: 10.1093/bmb/ldq033.
   PubMed Web of Science ®Google Scholar
• Goldsmith KA, Dyer MT, Schofield PM, et al. Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions. Health Qual Life Outcomes. 2009;7(1):96. https://pubmed.ncbi.nlm.nih.gov/19941657 doi: 10.1186/1477-7525-7-96.
   PubMedGoogle Scholar
• Dyer MTD, Goldsmith KA, Sharples LS, et al. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health Qual Life Outcomes. 2010;8(1):13. https://pubmed.ncbi.nlm.nih.gov/20109189 doi: 10.1186/1477-7525-8-13.
   PubMedGoogle Scholar
• Oberle W. Monte Carlo Simulations: number of Iterations and Accuracy. 2015; [cited 2023 Jun 10]. Available from: https://apps.dtic.mil/sti/pdfs/ADA621501.pdf.
   Google Scholar
• Drummond MF, Sculpher MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes (4th ed.). Oxford, New York: Oxford University Press; 2015. 464 p.
   Google Scholar
• Vemer P, Corro Ramos I, van Voorn GAK, et al. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34(4):349–361. Apr doi: 10.1007/s40273-015-0327-2.
   PubMed Web of Science ®Google Scholar
• Büyükkaramikli NC, Rutten-van Mölken MPMH, Severens JL, et al. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391–1408. doi: 10.1007/s40273-019-00844-y.
   PubMed Web of Science ®Google Scholar
• Cai R-P, Xu Y-L, Su Q. Dapagliflozin in patients with chronic heart failure: a systematic review and Meta-Analysis. Cardiol Res Pract. 2021;2021:6657380–6657312. doi: 10.1155/2021/6657380.
   PubMed Web of Science ®Google Scholar
• Docherty KF, Jhund PS, Anand I, et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation. 2020;142(17):1623–1632. doi: 10.1161/CIRCULATIONAHA.120.047480.
   PubMed Web of Science ®Google Scholar
• McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics. 2000;17(5):501–513. doi: 10.2165/00019053-200017050-00007.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Vaduganathan M, Chiu N, et al. Out-of-pocket costs for SGLT-2 (Sodium-Glucose transport protein-2) inhibitors in the United States. Circ Heart Fail. 2022;15(3):e009099. doi: 10.1161/CIRCHEARTFAILURE.121.009099.
   PubMed Web of Science ®Google Scholar
• Balkhi B, Alshayban D, Alotaibi NM. Impact of healthcare expenditures on healthcare outcomes in the Middle East and North Africa (MENA) region: a cross-Country comparison, 1995–2015. Front Public Heal. 2020;8:624962.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Fonarow GC, Breathett K, et al. ACC/AHA clinical performance and quality measures for adults with heart failure: a report of the American college of cardiology/American heart association task force on performance measures. Circ Cardiovasc Qual Outcomes. 2020;13(11):e000099.
   PubMed Web of Science ®Google Scholar
• Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction. JAMA Cardiol. 2021;6(8):926–935. doi: 10.1001/jamacardio.2021.1437.
   PubMed Web of Science ®Google Scholar
• Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 2018;11(1):1447828. https://pubmed.ncbi.nlm.nih.gov/29564962 doi: 10.1080/16549716.2018.1447828.
   PubMed Web of Science ®Google Scholar
• Qatar GDP Per Capita 1970–2023. Available from https://www.macrotrends.net/countries/QAT/qatar/gdp-per-capita.
   Google Scholar
• Thresholds for the cost–effectiveness of interventions: alternative approaches. 2023; [cited 2023 Jun 7]. Available from: https://apps.who.int/iris/handle/10665/271648.
   Google Scholar
• Qatar New Healthcare Insurance Law. 2024; [cited 2024 Jan 9]. Available from: https://www.trade.gov/market-intelligence/qatar-new-healthcare-insurance-law#:∼:text=All%20non%2DQatari%20nationals%20and,to%20receive%20basic%20medical%20services.&text=Qatari%20natio.
   Google Scholar
• Zaghloul N, Awaisu A, Mahfouz A, et al. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country. Int J Clin Pharm. 2022;44(6):1342–1350. doi: 10.1007/s11096-022-01464-x.
   PubMed Web of Science ®Google Scholar
• Sugiyama S, Jinnouchi H, Kurinami N, et al. Impact of dapagliflozin therapy on renal protection and kidney morphology in patients with uncontrolled type 2 diabetes mellitus. J Clin Med Res. 2018;10(6):466–477. https://pubmed.ncbi.nlm.nih.gov/29707088 doi: 10.14740/jocmr3419w.
   PubMedGoogle Scholar
• Mielck A, Vogelmann M, Leidl R. Health-related quality of life and socioeconomic status: inequalities among adults with a chronic disease. Health Qual Life Outcomes. 2014;12(1):58. doi: 10.1186/1477-7525-12-58.
   PubMedGoogle Scholar
• Quality of Life Index by Country 2023. 2023.
   Google Scholar